Literature DB >> 25755681

Nivolumab in NSCLC: latest evidence and clinical potential.

Raghav Sundar1, Byoung-Chul Cho2, Julie R Brahmer3, Ross A Soo4.   

Abstract

New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.

Entities:  

Keywords:  immune checkpoint modulator; nivolumab; non-small cell lung cancer; programmed death-1; programmed death-1 ligand

Year:  2015        PMID： 25755681      PMCID： PMC4346216          DOI： 10.1177/1758834014567470

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


  61 in total

Review 1.  Antitumor immune responses induced by ionizing irradiation and further immune stimulation.

Authors:  Benjamin Frey; Yvonne Rubner; Lorenz Kulzer; Nina Werthmöller; Eva-Maria Weiss; Rainer Fietkau; Udo S Gaipl
Journal:  Cancer Immunol Immunother       Date:  2013-09-20       Impact factor: 6.968

2.  Silica-induced chronic inflammation promotes lung carcinogenesis in the context of an immunosuppressive microenvironment.

Authors:  Javier Freire; Daniel Ajona; Gabriel de Biurrun; Jackeline Agorreta; Victor Segura; Elizabeth Guruceaga; Anne-Marie Bleau; Ruben Pio; David Blanco; Luis M Montuenga
Journal:  Neoplasia       Date:  2013-08       Impact factor: 5.715

3.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Authors:  Esra A Akbay; Shohei Koyama; Julian Carretero; Abigail Altabef; Jeremy H Tchaicha; Camilla L Christensen; Oliver R Mikse; Andrew D Cherniack; Ellen M Beauchamp; Trevor J Pugh; Matthew D Wilkerson; Peter E Fecci; Mohit Butaney; Jacob B Reibel; Margaret Soucheray; Travis J Cohoon; Pasi A Janne; Matthew Meyerson; D Neil Hayes; Geoffrey I Shapiro; Takeshi Shimamura; Lynette M Sholl; Scott J Rodig; Gordon J Freeman; Peter S Hammerman; Glenn Dranoff; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2013-09-27       Impact factor: 39.397

4.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

5.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

6.  Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.

Authors:  Stephanie G Downey; Jacob A Klapper; Franz O Smith; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Tamika E Allen; Catherine L Levy; Michael Yellin; Geoffrey Nichol; Donald E White; Seth M Steinberg; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2007-11-02       Impact factor: 12.531

7.  When progressive disease does not mean treatment failure: reconsidering the criteria for progression.

Authors:  Geoffrey R Oxnard; Michael J Morris; F Stephen Hodi; Laurence H Baker; Mark G Kris; Alan P Venook; Lawrence H Schwartz
Journal:  J Natl Cancer Inst       Date:  2012-08-27       Impact factor: 13.506

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

Review 9.  Immunotherapy in the treatment of non-small cell lung cancer.

Authors:  Raghav Sundar; Richie Soong; Byoung-Chul Cho; Julie R Brahmer; Ross A Soo
Journal:  Lung Cancer       Date:  2014-05-14       Impact factor: 5.705

10.  Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study.

Authors:  Yan-bin Chen; Chuan-Yong Mu; Jian-An Huang
Journal:  Tumori       Date:  2012-11
View more
  83 in total

1.  Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.

Authors:  Emily Coleman; Christine Ko; Feng Dai; Mary M Tomayko; Harriet Kluger; Jonathan S Leventhal
Journal:  J Am Acad Dermatol       Date:  2018-11-03       Impact factor: 11.527

Review 2.  Cellular immunotherapy for malignant gliomas.

Authors:  Yi Lin; Hideho Okada
Journal:  Expert Opin Biol Ther       Date:  2016-07-29       Impact factor: 4.388

Review 3.  Targeting neoantigens to augment antitumour immunity.

Authors:  Mark Yarchoan; Burles A Johnson; Eric R Lutz; Daniel A Laheru; Elizabeth M Jaffee
Journal:  Nat Rev Cancer       Date:  2017-02-24       Impact factor: 60.716

Review 4.  Novel Quantitative Imaging for Predicting Response to Therapy: Techniques and Clinical Applications.

Authors:  Kaustav Bera; Vamsidhar Velcheti; Anant Madabhushi
Journal:  Am Soc Clin Oncol Educ Book       Date:  2018-05-23

Review 5.  Nivolumab: a review in advanced squamous non-small cell lung cancer.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

Review 6.  Lung cancer: Biology and treatment options.

Authors:  Hassan Lemjabbar-Alaoui; Omer Ui Hassan; Yi-Wei Yang; Petra Buchanan
Journal:  Biochim Biophys Acta       Date:  2015-08-19

7.  The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo.

Authors:  Lu Dai; Charles D Smith; Maryam Foroozesh; Lucio Miele; Zhiqiang Qin
Journal:  Int J Cancer       Date:  2018-01-04       Impact factor: 7.396

Review 8.  Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.

Authors:  Jeffrey S Weber; Michael Postow; Christopher D Lao; Dirk Schadendorf
Journal:  Oncologist       Date:  2016-07-08

Review 9.  Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.

Authors:  Maria I Carlo; Martin H Voss; Robert J Motzer
Journal:  Nat Rev Urol       Date:  2016-06-21       Impact factor: 14.432

10.  Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer.

Authors:  Grit S Herter-Sprie; Shohei Koyama; Houari Korideck; Josephine Hai; Jiehui Deng; Yvonne Y Li; Kevin A Buczkowski; Aaron K Grant; Soumya Ullas; Kevin Rhee; Jillian D Cavanaugh; Neermala Poudel Neupane; Camilla L Christensen; Jan M Herter; G Mike Makrigiorgos; F Stephen Hodi; Gordon J Freeman; Glenn Dranoff; Peter S Hammerman; Alec C Kimmelman; Kwok-Kin Wong
Journal:  JCI Insight       Date:  2016-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.